Stay updated with breaking news from Protein Engineering. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A South Australian-developed SARS-CoV-19 vaccine is preparing to progress to the final stages of human clinical trials after early animal testing confirmed its safety and effectiveness in preventing COVID-19 lung infection.
While biochemistry is the study of chemical processes taking place within living organisms, biotechnology is the ultimate product of these discoveries.
ACTengine patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201, IMA202 or IMA203 across different cancer indicationsTCR Bispecifics pipeline
Visiongain has published a new report on Global Protein Engineering Market Report Forecast 2021-2031. Forecast By Product (Consumables, Instruments, and Software & Services) By Protein Type (Monoclonal Antibodies, Insulin, Vaccines, Erythropoietins, Colony-Stimulating Factors, Growth Hormones, Coagulation Factors, Interferons, Other Proteins) By Technology (Rational Protein Design, Irrational Protein Design, Hybrid Protein Design) By End-User (Biopharmaceutical Companies, Contract Research Organ
Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress ACCESSWIRE Advancing Dyadic 's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial Goal of validating that C1 produced proteins are safe in humans and to accelerate adoption and use of C1 technology platform for the development and manufacture of vaccines and therapeutics Goal of bringing larger quantities of lower cost COVID-19 vaccines that can be used as a prime and booster to existing vaccines Engaged CR2O to manage and support further preclinical and c...